Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E16.18 EPS (ttm)10.26 Insider Own0.10% Shs Outstand736.45M Perf Week-7.81%
Market Cap122.28B Forward P/E13.02 EPS next Y12.75 Insider Trans0.00% Shs Float735.42M Perf Month-3.81%
Income7.72B PEG2.53 EPS next Q3.00 Inst Own80.50% Short Float1.19% Perf Quarter13.56%
Sales22.99B P/S5.32 EPS this Y13.10% Inst Trans-1.79% Short Ratio2.22 Perf Half Y-3.18%
Book/sh40.59 P/B4.09 EPS next Y3.56% ROA10.10% Target Price186.07 Perf Year14.55%
Cash/sh51.71 P/C3.21 EPS next 5Y6.41% ROE25.90% 52W Range131.83 - 184.21 Perf YTD14.35%
Dividend4.60 P/FCF18.76 EPS past 5Y20.50% ROI13.00% 52W High-9.86% Beta1.25
Dividend %2.77% Quick Ratio3.90 Sales past 5Y8.10% Gross Margin81.90% 52W Low25.95% ATR3.28
Employees19200 Current Ratio4.10 Sales Q/Q7.70% Oper. Margin42.60% RSI (14)39.56 Volatility1.82% 1.54%
OptionableYes Debt/Eq1.16 EPS Q/Q10.50% Profit Margin33.60% Rel Volume1.13 Prev Close167.45
ShortableYes LT Debt/Eq1.01 EarningsFeb 02 AMC Payout38.70% Avg Volume3.96M Price166.04
Recom2.30 SMA20-5.89% SMA50-0.60% SMA2004.32% Volume3,910,300 Change-0.84%
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Mar-23-17 04:00PM  European Commission Approves AMGEVITA (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases PR Newswire
03:40PM  Stock Research Reports for Amgen, Berkshire & Walgreens
02:07PM  Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
10:57AM  Biotechs Back in the Doghouse After Failed Rally at Investopedia
09:00AM  How This Company Is Taking on Amgen at Motley Fool
Mar-22-17 03:21PM  Biotech giant plans $25M Tampa investment, 450 jobs at bizjournals.com
11:25AM  Health ETF Wobbles As Vote On Bill To Replace ObamaCare Nears; Gold Gains
09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
08:33AM  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
Mar-21-17 04:54PM  Sanofi and Regeneron Sue Amgen over Eczema Drug at Investopedia
02:45PM  Sanofi-Genzyme files preemptive legal strike to protect eczema drug at bizjournals.com
12:49PM  4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
12:33PM  Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims
11:00AM  ONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment
09:25AM  3 Biotech Stocks That Are Broker Favorites
Mar-20-17 08:08PM  Esperion Therapeutics Inc (ESPR): Get It While Its Cheap at Insider Monkey
05:02PM  Here's What Pushed Esperion Therapeutics Inc Stock Higher Today at Motley Fool
04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
01:18PM  Why Amgen's Success Was a Big Disappointment at Motley Fool
10:26AM  Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:40AM  There's a Middle Ground in Amgen's Drug-Price Battle
07:32AM  Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug at Forbes
04:55AM  Lowering LDL Levels with Repatha(R) (evolocumab) Did Not Adversely Affect Cognitive Function in Landmark Phase 3 Study PR Newswire
03:28AM  Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues PR Newswire
01:00AM  Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View
Mar-19-17 02:00PM  Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients PR Newswire
11:01AM  Is Trump Bad for Healthcare Stocks? These 4 Winners Don't Think So at Motley Fool
Mar-18-17 08:00AM  Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study PR Newswire
Mar-17-17 11:47PM  Amgens Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal -6.38%
11:43PM  [$$] Amgens Money-Back Guarantee at The Wall Street Journal
07:18PM  Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal
07:15PM  How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More
05:44PM  Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis
04:59PM  The Biggest Loser: Amgen Drops 6.4% at Barrons.com
04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
04:49PM  Amgen discounts cholesterol drug, but payers want more
04:30PM  Why Amgen, AmTrust Financial Services, and BRF Slumped Today at Motley Fool
04:28PM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
04:19PM  Markets Right Now: Early gain for stocks fades at close
04:07PM  New cholesterol-fighting drug slashes heart attack risk, but at a steep price; Amgen shares drop at CNBC
04:03PM  Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
02:56PM  Amgen, Esperion, AmTrust Financial and More: What is Going On With These Falling Stocks? at Insider Monkey
02:22PM  Nasdaq Hits Record High As Stocks Slowly Gain Steam
01:51PM  [$$] Amgen's Money-Back Guarantee at The Wall Street Journal
01:32PM  Stocks Turn Higher Even as Amgen Leads Another Health Care Selloff
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
01:03PM  CVS Health says Amgen data may increase eligible patients by millions
01:03PM  Amgen Blew ItFor Medicines Co., Esperion Too at Barrons.com
01:00PM  Amgen's Repatha Reduced Heart Attack, Stroke Risk at Investopedia
12:52PM  US STOCKS-Wall St flat as tech gains offset weakness in banks
12:46PM  Why Amgen's Getting Crushed at Barrons.com
12:40PM  Be Patient With Amgen After Its Major Breakdown
12:04PM  Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall at TheStreet
11:46AM  GLOBAL MARKETS-World stocks hover near peaks, dollar extends slide Reuters
11:38AM  US STOCKS-Wall St edges lower as financial stocks drag
11:22AM  Express Scripts says Amgen data opens door to patients
11:03AM  [video]AveXis, Esperion and Amgen Among Biotech Movers
10:38AM  Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate
10:37AM  This Key Measure Shows the S&P Could Be Headed for a 5% Pullback
10:09AM  US stocks mixed, still on pace for yet another winning week
10:04AM  US STOCKS-Wall St little changed as healthcare stocks weigh
09:33AM  5 Biotech Companies To Watch In 2017
09:00AM  Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues PR Newswire
09:00AM  Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study
08:48AM  What are Sanofi's (SNY) Strengths and Challenges in 2017?
Mar-16-17 05:52PM  Billion dollar boost for Amgen?
04:09PM  Markets Right Now: US indexes waver to mixed close
02:30PM  5 Biotech Companies Set for Major Breakouts In 2017
10:49AM  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
10:00AM  Does Amgen Offer a Great Value Buying Opportunity Right Now?
08:46AM  Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
08:05AM  Life-Saving Device Could Transform The Medical Market In 2017
Mar-15-17 07:01PM  Cramer: The Airlines and Health-Care Names Are Really Soaring
11:48AM  Jim Cramer: Amgen's Pipeline Positions It Well to Withstand a Rate Hike
09:55AM  Cramer's Stop Trading: Amgen's pipeline
Mar-14-17 04:15PM  Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology' PR Newswire
04:06PM  Amgen Could Boost Rivals On Positive Heart-Disease Study: Analyst
04:00PM  Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions PR Newswire
10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar-13-17 04:37PM  Amgen Tops Heart Study As Rivals Regeneron, Sanofi Chill In Court
09:24AM  Amgen's Repatha lowers need for cholesterol-lowering procedure
09:20AM  Amgen says its Repatha reduced need for high cholesterol therapy in late-stage clinical trial at MarketWatch
09:00AM  Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study PR Newswire
08:00AM  Early movers: MBLY, INTC, YHOO, BA, IT, NAV, DISH, F, AMGN & more at CNBC
01:00AM  Data on heart benefits of Amgen drug is key to unlocking sales
Mar-11-17 11:41AM  Which Biotech Is the Best Dividend Stock? at Motley Fool
Mar-10-17 07:27PM  World economy stronger than you think
06:53PM  Cramer's game plan: The world economy is stronger than yo...
06:15PM  Cramer's game plan: The world economy is stronger than you think this stock will prove it at CNBC
04:39PM  Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging'
01:12PM  AbbVie Stock Upgraded: What You Need to Know at Motley Fool
10:30AM  Major Biotechs See a Retreat in Short Interest
09:28AM  Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
Mar-09-17 04:31PM  Momo Dives Despite Price Target Hike; UBS Initiates Biotechs; Mercury Is A Buy
03:52PM  Pro: Opportunitiy if you can get beyond overall market an...
10:01AM  Coverage initiated on Amgen by UBS
09:21AM  AbbVie at the Cowen Healthcare Conference: 4 Things You'll Want to Know at Motley Fool
Mar-08-17 04:47PM  Pharma says high prices fund drug development but this study finds otherwise at MarketWatch
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM